Clinical trial
A Randomized, Open-label, Interventional, Real-world Study to Compare the Efficacy and Safety of QL0605 Administered at Different Timepoints After Chemotherapy.
NCT06616571 is registered in ClinicalTrials.gov with Qilu Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Open-label, Interventional, Real-world Study to Compare the Efficacy and Safety of QL0605 Administered at Different Timepoints After Chemotherapy.
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.
- Phase
- Phase 4
- Overall status
- Recruiting
- Start date
- September 19, 2024
- Completion date
- December 30, 2025
- Enrollment
- 336 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.